Physician profile
Sara E Singer
NPI 1558756031
$581.29
in general payments reported to CMS, 2019-2025
12 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.51 · 2023: $163 · 2024: $81.70 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $99.51 | 2021 | |
| Janssen Biotech, INC. | $72.54 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $68.68 | 2023 | Pomalyst |
| Sobi, INC | $63.61 | 2024 | |
| Gilead Sciences, INC. | $61.16 | 2025 | |
| Novartis Pharmaceuticals Corporation | $54.80 | 2024-2025 | |
| Genentech USA, INC. | $39.51 | 2023-2025 | Polivy, Phesgo |
| Pharmacosmos Therapeutics INC. | $32.43 | 2025 | Monoferric |
| Daiichi Sankyo INC. | $28.27 | 2025 | |
| Merck Sharp & Dohme LLC | $23.33 | 2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $19.05 | 2023 | |
| Pharmaessentia USA Corporation | $18.40 | 2025 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.